Surgical treatment of primary breast cancer in the neoadjuvant setting (Q38212607)

31 August 2017

title

Surgical treatment of primary breast cancer in the neoadjuvant setting (English)

1 reference

31 August 2017

1 reference

S Kümmel

1

1 reference

31 August 2017

J Holtschmidt

series ordinal

2

1 reference

31 August 2017

S Loibl

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

19 May 2014

1 reference

British Journal of Surgery

31 August 2017

published in

1 reference

31 August 2017

volume

101

1 reference

31 August 2017

issue

8

1 reference

31 August 2017

page(s)

912-924

1 reference

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

31 August 2017

cites work

1 reference

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

21 January 2018

1 reference

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

21 January 2018

1 reference

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

21 January 2018

1 reference

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

21 January 2018

1 reference

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study

21 January 2018

1 reference

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study

21 January 2018

1 reference

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer

21 January 2018

1 reference

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar

21 January 2018

1 reference

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0

21 January 2018

1 reference

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results

21 January 2018

1 reference

The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).

21 January 2018

1 reference

Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.

21 January 2018

1 reference

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

21 January 2018

1 reference

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

21 January 2018

1 reference

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

21 January 2018

1 reference

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

21 January 2018

1 reference

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study

21 January 2018

1 reference

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

21 January 2018

1 reference

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

Response-guided neoadjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes

21 January 2018

1 reference

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer

21 January 2018

1 reference

Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?

21 January 2018

1 reference

Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy

21 January 2018

1 reference

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy

21 January 2018

1 reference

Impact of neoadjuvant chemotherapy on wound complications after breast surgery

21 January 2018

1 reference

Neoadjuvant therapy and breast cancer surgery: a closer look at postoperative complications

21 January 2018

1 reference

Effect of neoadjuvant chemotherapy on outcomes of immediate free autologous breast reconstruction

21 January 2018

1 reference

Impact of Chemotherapy on Postoperative Complications After Mastectomy and Immediate Breast Reconstruction

21 January 2018

1 reference

A review on bevacizumab and surgical wound healing: an important warning to all surgeons

21 January 2018

1 reference

Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?

21 January 2018

1 reference

Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction

21 January 2018

1 reference

Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype

21 January 2018

1 reference

Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy.

21 January 2018

1 reference

Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

21 January 2018

1 reference

Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.

21 January 2018

1 reference

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

21 January 2018

1 reference

Time to stop operating on breast cancer patients with pathological complete response?

21 January 2018

1 reference

Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/BJS.9545

1 reference

31 August 2017

1 reference